Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
16036182
DOI
10.1016/j.jcv.2004.12.010
PII: S1386-6532(05)00002-8
Knihovny.cz E-zdroje
- MeSH
- časové faktory MeSH
- dospělí MeSH
- HIV séropozitivita farmakoterapie MeSH
- HIV-1 účinky léků fyziologie MeSH
- inhibitory HIV-proteasy terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- Lopinavir MeSH
- počet CD4 lymfocytů MeSH
- pyrimidinony terapeutické užití MeSH
- ritonavir terapeutické užití MeSH
- RNA virová krev MeSH
- výsledek terapie MeSH
- záchranná terapie * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- inhibitory HIV-proteasy MeSH
- Lopinavir MeSH
- pyrimidinony MeSH
- ritonavir MeSH
- RNA virová MeSH
BACKGROUND: The cohort of 19 patients on LPV/r salvage regimen was followed for the period of up to 37.5 months. Patient's virologic response was evaluated with regard to the various baseline characteristics. RESULTS: A 73.7% of patients (14 out of 19) achieved viral suppression during the first three months of treatment, either complete (47.4%) or partial (26.3%). This effect was only transient in five cases (virologic rebound emerged after 9 months of treatment on average) and in nine cases the treatment was successful in the long-term analysis (HIV RNA plasma level still undetectable at 31st month of the therapy on average with maximum of 36 months). We analyzed the link between the virologic response and possible predictive factors of treatment efficiency, such as lopinavir mutation score, various individual mutations, previous PI exposure, etc. We also describe changes in the PR sequence associated with poor response to the salvage therapy to LPV/r. CONCLUSIONS: The results of LPV/r salvage therapy were encouraging. About 47% of patients from our study achieved stable suppression of viral replication for 31 months on average. LPV/r proved to be potent inhibitor despite unfavourable prognosis.
Citace poskytuje Crossref.org